Balyasny Asset Management
CMPX icon

Balyasny Asset Management’s Compass Therapeutics CMPX Stock Holding History

Balyasny Asset Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-332,100
Closed -$631K – 2891
2025
Q1 		$631K Buy
+332,100
New +$883K ﹤0.01% 2190

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management's CMPX Position: Q1 2026 in Review

Balyasny Asset Management reduced its Compass Therapeutics (CMPX) stake by 30% in Q1 2026, selling an estimated $2.74M and leaving 1,119,090 shares worth $5.92M. The position accounts for 0.01% of the portfolio, ranked #1289.

Balyasny Asset Management first reported a position in CMPX in Q4 2022 and has held it in 5 quarters since. The position peaked at $9.89M in Q3 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Balyasny Asset Management held 1,119,090 shares of Compass Therapeutics worth $5.92M as of Q1 2026.
  • Balyasny Asset Management sold 474,185 Compass Therapeutics shares in Q1 2026, an estimated $2.74M.
  • Compass Therapeutics made up 0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1289 holding.
  • Balyasny Asset Management first reported a position in Compass Therapeutics in Q4 2022 and has held it in 5 quarters since.
  • Balyasny Asset Management's Compass Therapeutics position peaked at $9.89M in Q3 2025.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.